检索历史 清除

摘要Breast canceris diverse in their natural history and in their responsiveness to treatments.It is urgent to generate candidate biomarkers for the stratification of patients and personaliza-tion of therapy to avoid overtreatment or inadequate treatment.Long noncoding RNAs(lncRNAs) have been found to be pervasively transcribed in the genome and played critical roles in cancer progression.A lot of lncRNAs have been reported as potential prognostic biomarkers and therapeutic targets in multiple cancers.In this study,we demonstrated that FGF14 antisense RNA 2 (FGF14-AS2),a novel long non-coding RNA,was significantly down-regulated in breast cancer tissue compared with adjacent normal tissue both in validated cohort and TCGA cohort.Reduced expression of FGF14-AS2 was correlated with larger tumor size,more lymph node metastasisand advanced clinical stage in both cohorts.Kaplan-Meier analysis indicated that patients with lower FGF14-AS2 expression had a worse overall survival.Moreover,multivariate analysis revealed that decreased expression of FGF14-AS2was an independent predictor of overall survival.Together,these results suggested that FGF14-AS2 involved in the progress of breast cancer and might act as a tumor suppressor gene.To the best ofour knowledge,it was firstly reported that FGF14-AS2 was involved in cancer.This study provided a potential newmarker and a target for gene therapy in breast cancer treatment.